- Home
- HALO
as 10-17-2025 3:57pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $73.09 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.37 | EPS Growth: | 68.93 |
| 52 Week Low/High: | $42.01 - $79.50 | Next Earning Date: | 11-04-2025 |
| Revenue: | $1,178,672,000 | Revenue Growth: | 34.97% |
| Revenue Growth (this year): | 32.57% | Revenue Growth (next year): | 23.77% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 3 '25 | Sell | $70.14 | 20,000 | $1,380,638.14 | 733,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 2 '25 | Sell | $72.35 | 20,000 | $1,424,082.70 | 733,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 1 '25 | Sell | $75.40 | 20,000 | $1,507,024.28 | 733,719 | |
| Connaughton Bernadette | HALO | Director | Oct 1 '25 | Sell | $75.40 | 2,000 | $150,481.00 | 44,952 | |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Sep 22 '25 | Sell | $78.25 | 2,227 | $173,584.49 | 22,079 | |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Sep 10 '25 | Sell | $75.61 | 20,000 | $1,514,267.12 | 22,079 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 4 '25 | Sell | $74.36 | 20,000 | $1,480,772.20 | 733,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 3 '25 | Sell | $74.43 | 20,000 | $1,488,726.00 | 733,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 2 '25 | Sell | $73.44 | 20,000 | $1,475,128.09 | 733,719 | |
| Connaughton Bernadette | HALO | Director | Sep 2 '25 | Sell | $73.15 | 4,000 | $294,736.24 | 44,952 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Pharmaceutical Technology
17 days ago
Halozyme eyes microparticles in $900m Elektrofi acquisition
Insider Monkey
18 days ago
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target
MT Newswires
18 days ago
Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT Newswires
18 days ago
Halozyme to Acquire Elektrofi for $750 Million Upfront Plus up to $150 Million in Milestone Payments
PR Newswire
18 days ago
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
BioPharma Dive
18 days ago
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech
Investor's Business Daily
19 days ago
Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.